Trial Profile
Phase II, Open, Randomised, Parallel Group, Noncomparative Multicentre Study to Assess the Efficacy and Safety of Repeated Subcutaneous (S.C.) Administration of Different Doses of BIM 23A760 in Acromegalic Patients
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 05 Oct 2021
Price :
$35
*
At a glance
- Drugs Onzigolide (Primary)
- Indications Acromegaly
- Focus Therapeutic Use
- Acronyms TULIPIA
- Sponsors Ipsen
- 14 May 2014 New trial record